News

BRAINBox Solutions Announces Initial Series B Investments to Support U.S. Regulatory Clearance, Initial Commercialization of BRAINBox TBI Concussion Diagnostic/Prognostic Test

BRAINBox Solutions today announced initial investments into the company’s Series B financing to support U.S. regulatory clearance and initial commercialization of its BRAINBox TBI concussion diagnostic/prognostic test in adults and completion of a clinical study in pediatric patients. Genoa Ventures is leading the financing, which includes other current and new investors.

“We have made significant clinical and pre-commercial progress in developing the BRAINBox TBI test,” said Donna Edmonds, BRAINBox Solutions’ CEO. “We are working with selected platform partners as we determine the fastest path to market for use in both point-of-care and emergency department settings.” She noted that in addition to the adult population, the company is developing BRAINBox TBI tests for pediatric patients, and, through a National Institutes of Health grant, for geriatric patients.

“The BRAINBox TBI test is the first to integrate physiologic and functional testing, an approach that is designed to maximize sensitivity and specificity, and provide objective criteria for the diagnosis and prognosis of acute traumatic encephalopathy, commonly known as concussion,” said W. Frank Peacock, MD FACEP, FACC, FESC, the study’s Principal Investigator and Professor, Vice Chair for Research, Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine.

The company’s key progress and achievements include:

HeadSMART II trial – The pivotal trial to support FDA clearance in adults has enrolled 2000 subjects, including subjects for the company’s Normative Data Base in support of the Neurocognitive Component of the Multi-Marker Multi-Modality Product. The company has presented its clinical data at several medical meetings over the past several months.

Pediatric Test – The company entered a funded collaboration with USA Hockey, to evaluate biomarkers in blood and saliva for concussion in elite girls and boys high school hockey players. The study aims to add to the information in the development of the company’s pediatric test by providing objective evidence of neurocognitive changes due to head impacts. The company’s pilot clinical trial in pediatric subjects is currently underway.

“In the current healthcare environment, where priorities include appropriate resource utilization, timely value-based care and patient satisfaction, both patients and clinicians strongly desire a quantitative approach that guides the next step in concussion management,” commented Chad Cannon MD, Chair & Clinical Service Chief, Professor, Department of Emergency Medicine at University of Kansas Medical Center and The University of Kansas Health System, and a Principal Investigator for the HeadSMART II trial.

 

Learn more here.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital